Monthly M&A Insider: February20 February 2009

This is the definitive crib sheet to see what is happening in global M&A. This edition comprises of over 200 pages of comment, data and statistics on the key issues in key M&A territories.

Table of Contents

1. Introduction

2. If cash is king then China rules the M&A landscape

3. Toxic turnaround: Is private equity poised to breath life into the real estate and and mortgage sectors?

4. European private equity buyouts jolted out of hibernation

5. Remedying global Pharma’s ailments

6. North America

7. Latin America

8. Asia-Pacific

9. China

10. Japan

11. Australia

12. Europe

13. UK

14. Germany

15. France

16. Italy

17. Benelux

18. Iberia

19. Nordic

20. CEE/CIS

21. Russia

January deal flow was dominated by two large-cap Pharma, Medical & Biotech transactions, namely the $66.2bn (€50.2bn) and $43.2bn (€ 33.8bn) acquisitions of Wyeth and a 14% stake in Genentech respectively. Pfizer announced its bid for Wyeth towards the end of January, with Roche, a Swiss Healthcare group, announcing its offer for a minority stake buy in Genentech on the penultimate day of the month.

Other notable corporate tie-ups over the period were focused in the Energy space and included the $12.4bn (€9.3bn) acquisition of Essent, the Dutch energy-generator and provider by RWE AG, its German counterpart, as well as the largest Asian M&A transaction for the month – the $6.6bn (€4.9bn) buy of a 79% stake in PetroVietnam Southern Gas Joint Stock Company by PetroVietnam Gas Corporation, both Vietnamese businesses with a focus in the gas industry.

To view this month's report click here

We hope you find this report useful and we would particularly welcome any feedback or questions you might have.

Back to Remark